Navigation Links
MultiCell Technologies Receives Final Payment Under QTDP Program

WOONSOCKET, R.I., Jan. 3, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has received the final cash grant award payment of $303,102 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program.  The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or cash grant equal to eligible costs and expenses.

To be eligible, a therapeutic development project must: (i) have the potential to develop new treatments that address "unmet medical needs" or chronic and acute diseases; (ii) reduce long-term health care costs; (iii) represent a significant advance in finding a cure for cancer; (iv) advance U.S. competitiveness in the fields of life, biological, and medical sciences; or (v) create or sustain well-paying jobs, either directly or indirectly. 

"We are pleased that our drug development programs for the treatment of cancer (MCT-465/485 and MCT-475) and for the treatment of fatigue in multiple sclerosis patients (MCT-125) qualified for certification under the QTDP program," said W. Gerald Newmin, Chairman and CEO of MultiCell.   

MultiCell applied for and was awarded a combined total of $1,466,875 as qualifying expenses under the QTDP program. The Company elected to take a cash grant in the amount of $733,437 rather than a $1,466,875 future tax credit. The Company had earlier received payments of $430,335 under this grant in 2010 and 2011 leaving the recently paid balance of $303,102. 

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc., and its majority owned subsidiary Xenogenics Corporation, are developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, cancer, cardiac and hepatic disease and some types of autoimmune diseases. For more information about MultiCell Technologies, please visit

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2010, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell and University Health Network Will Evaluate Two Potential Therapies for Liver Cancer Treatment
2. MultiCell Technologies is Granted Stem Cell Patent
3. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
4. MultiCell Technologies Launches New Web Site
5. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
6. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
7. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
8. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
9. Transdermal Drug Delivery - Technologies, Markets, and Companies
10. Pulmonary Drug Delivery Systems: Technologies and Global Markets
11. Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View
Post Your Comments:
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... held in San Francisco, CA ... solutions to the coronary marketplace. During a satellite ... in Stent Design to Minimize Restenosis", a renowned ... currently available Medinol NIRxcell™ CoCr Coronary Stent System ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
(Date:12/1/2015)...  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company ... cardiovascular conditions via the inhalation route, today announced that ... Australia . InCarda is planning to undertake its ... in the first half of 2016. The company ... Adelaide and Melbourne.  In addition, ...
Breaking Medicine Technology:
(Date:12/1/2015)... D.C. (PRWEB) , ... December 01, 2015 , ... ... updated, comprehensive website detailing the important role that meat and poultry play ... in meat and poultry, a nutrition quiz where visitors can check their “meat ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services (“Integrated ... Industries International, LLC (“JII”). , With support from JII, Integrated Rental is poised ... hospitals, surgery centers, clinics, research labs and medical facilities across the United States. ...
(Date:12/1/2015)... ... 01, 2015 , ... Califia Farms , one of the fastest growing ... won top honors in Beverage World Magazine’s Global Packaging Design Awards, taking home the ... been selected as a 2015 U.S.A. Taste Champion in the American Masters of Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... December ... seen vast improvements in scientific research and discoveries, leading us to better understand ... and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
Breaking Medicine News(10 mins):